Yifah Yaron

1.9k total citations · 1 hit paper
17 papers, 1.4k citations indexed

About

Yifah Yaron is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, Yifah Yaron has authored 17 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 5 papers in Hematology. Recurrent topics in Yifah Yaron's work include Thyroid Cancer Diagnosis and Treatment (5 papers), CAR-T cell therapy research (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Yifah Yaron is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (5 papers), CAR-T cell therapy research (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Yifah Yaron collaborates with scholars based in United States, France and Italy. Yifah Yaron's co-authors include Steven I. Sherman, Patrick Schöffski, Michael C. Kreißl, Manisha H. Shah, Douglas W. Ball, Marcia S. Brose, Lisa Licitra, Haythem Ali, Rossella Elisei and Ezra E.W. Cohen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and American Journal of Obstetrics and Gynecology.

In The Last Decade

Yifah Yaron

17 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cabozantinib in Progressive Medullary Thyroid Cancer

2013 850 citations Rossella Elisei, Martin Schlumberger et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Yifah Yaron

Since Specialization

Citations

This map shows the geographic impact of Yifah Yaron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yifah Yaron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yifah Yaron more than expected).

Fields of papers citing papers by Yifah Yaron

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yifah Yaron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yifah Yaron. The network helps show where Yifah Yaron may publish in the future.

Co-authorship network of co-authors of Yifah Yaron

This figure shows the co-authorship network connecting the top 25 collaborators of Yifah Yaron. A scholar is included among the top collaborators of Yifah Yaron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yifah Yaron. Yifah Yaron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	P-292 Ongoing phase 1 study of HPN217, a half-life extended tri-specific T cell activating construct (TriTAC) targeting B cell maturation antigen (BCMA) for relapsed/refractory multiple myeloma (MM) 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Sumit Madan, (unknown), Brea Lipe, Eva Medvedova, Andrew J. Cowan, (unknown), Leif Bergsagel, Xavier Leleu, Cyrille Touzeau, Daniel Morillo, Albert Oriol, Raya Mawad, (unknown), Salomon Manier, Yifah Yaron, Patrick P. Ng, Al‐Ola Abdallah	1
2	Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM) 2023 ·Blood ·Sumit Madan, Caitlin Costello, Brea Lipe, Andrew J. Cowan, Eva Medvedova, (unknown), P. Leif Bergsagel, Xavier Leleu, Cyrille Touzeau, Daniel Morillo, Albert Oriol, Raya Mawad, (unknown), Salomon Manier, Yifah Yaron, Banmeet S. Anand, Al‐Ola Abdallah	8
3	Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers. 2022 ·Journal of Clinical Oncology ·Melissa L. Johnson, Grace K. Dy, Hirva Mamdani, Afshin Dowlati, Adam J. Schoenfeld, Jose M. Pacheco, Rachel E. Sanborn, Smitha Menon, (unknown), Yifah Yaron, Himisha Beltran	36
4	Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM) 2022 ·Blood ·Al‐Ola Abdallah, Andrew J. Cowan, Xavier Leleu, Cyrille Touzeau, Brea Lipe, Eva Medvedova, (unknown), (unknown), P. Leif Bergsagel, Raya Mawad, (unknown), (unknown), Albert Oriol, Yifah Yaron, Patrick P. Ng, Sumit Madan	11
5	Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC). 2021 ·Journal of Clinical Oncology ·Johann S. de Bono, Lawrence Fong, Tomasz M. Beer, Xīn Gào, Daniel M. Geynisman, Howard A. Burris, James Strauss, Kevin D. Courtney, David I. Quinn, David James VanderWeele, Yifah Yaron, Che‐Leung Law, Mark N. Stein	28
6	Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non–Small-Cell Lung Cancer 2018 ·Clinical Lung Cancer ·Hiroshi Nokihara, Makoto Nishio, Noboru Yamamoto, Yutaka Fujiwara, Hidehito Horinouchi, Shintaro Kanda, Atsushi Horiike, Fumiyoshi Ohyanagi, Noriko Yanagitani, Linh T. Nguyen, Yifah Yaron, (unknown), Tomohide Tamura	29
7	Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma 2017 ·Annals of Oncology ·Martin Schlumberger, Rossella Elisei, Stefan Müller, Patrick Schöffski, Marcia S. Brose, Manisha H. Shah, Lisa Licitra, Jolanta Krajewska, Michael C. Kreißl, Bruno Niederle, Ezra E.W. Cohen, Lori J. Wirth, Haythem Ali, D O Clary, Yifah Yaron, Milan Mangeshkar, Douglas W. Ball, Barry D. Nelkin, Steven I. Sherman	170
8	A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer 2017 ·Cancer Chemotherapy and Pharmacology ·Heather A. Wakelee, Scott Gettinger, Jeffrey A. Engelman, Pasi A. Jänne, Howard West, Deepa S. Subramaniam, Joseph L. Leach, (unknown), Yifah Yaron, Dale Miles, Primo N. Lara	29
9	Assessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induced changes in serum electrolytes 2017 ·Cancer Chemotherapy and Pharmacology ·Dale Miles, Steven Lacy, (unknown), (unknown), Yifah Yaron, Linh T. Nguyen	8
10	Initial Results from a Cohort in a Phase 2a Study (GBT440-007) Evaluating Adolescents with Sickle Cell Disease Treated with Multiple Doses of GBT440, a HbS Polymerization Inhibitor 2017 ·Blood ·Carolyn Hoppe, Adlette Inati, R. Clark Brown, Winfred C. Wang, Victor R. Gordeuk, Robert I. Liem, Gerald M. Woods, Connie M. Piccone, Erica Fong, Ganesh Balaratnam, (unknown), Margaret Tonda, Carla Washington, Yifah Yaron, (unknown)	6
11	Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline. 2015 ·Journal of Clinical Oncology ·Martin Schlumberger, Rossella Elisei, Stefan Müller, Patrick Schöffski, Marcia S. Brose, Manisha H. Shah, Lisa Licitra, Barbara Jarząb, В. С. Медведев, Michael C. Kreißl, Ezra E.W. Cohen, Lori J. Wirth, Haythem Ali, Colin Hessel, Yifah Yaron, Douglas W. Ball, Barry D. Nelkin, Steven I. Sherman	23
12	Cabozantinib in Progressive Medullary Thyroid Cancer breakdown → 2013 ·Journal of Clinical Oncology ·Rossella Elisei, Martin Schlumberger, Stefan Müller, Patrick Schöffski, Marcia S. Brose, Manisha H. Shah, Lisa Licitra, Barbara Jarząb, В. С. Медведев, Michael C. Kreißl, Bruno Niederle, Ezra E.W. Cohen, Lori J. Wirth, Haythem Ali, Colin Hessel, Yifah Yaron, Douglas W. Ball, Barry D. Nelkin, Steven I. Sherman	850
13	Long-term disease control of ≥2 years achieved with cabozantinib in subjects with metastatic medullary thyroid carcinoma on a phase I study. 2013 ·Journal of Clinical Oncology ·Ezra E.W. Cohen, David S. Hong, David G. Pfister, Ravi Salgia, Barbara Burtness, Roger B. Cohen, Douglas W. Ball, Ranee Mehra, Milan Mangeshkar, Yifah Yaron, Frauke Bentzien, Razelle Kurzrock	1
14	An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. 2012 ·Journal of Clinical Oncology ·Patrick Schöffski, Rossella Elisei, Stefan Müller, Marcia S. Brose, Manisha H. Shah, Lisa Licitra, Barbara Jarząb, В. С. Медведев, Michael C. Kreißl, Bruno Niederle, Ezra E.W. Cohen, Lori J. Wirth, Haythem Ali, Colin Hessel, Yifah Yaron, Douglas W. Ball, Barry D. Nelkin, Steven I. Sherman, Martin Schlumberger, (unknown)	68
15	A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC). 2010 ·Journal of Clinical Oncology ·Heather A. Wakelee, Scott Gettinger, J. A. Engelman, Pasi A. Jänne, Howard West, Deepa S. Subramaniam, Joseph W. Leach, (unknown), Yifah Yaron, Primo N. Lara	55
16	A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse 2009 ·Journal of Clinical Oncology ·John de Groot, Michael D. Prados, (unknown), Stephanie Robertson, Yifah Yaron, A. G. Sorensen, A. Norton, Tracy T. Batchelor, Jan Drappatz, Patrick Y. Wen	34
17	In utero treatment of obstructing ureterocele 1997 ·American Journal of Obstetrics and Gynecology ·(unknown), E. Todd Schroeder, Rubén A. Quintero, Andrew L. Freedman, C. Sudz, Yifah Yaron, (unknown), (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact